On 9/24/25, Seres Therapeutics Inc (NASDAQ: MCRB) stock enjoyed a major increase of 10.4%, closing at $19.39. Moreover, trading volume in this advance was exceptionally high at 204% of normal. Relative to the market the stock has been weak over the last nine months but has risen 11.4% during the last week.
Current PriceTarget Research Rating
Seres Therapeutics is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment